A pharma giant is moving past one patent cliff — but another is already looming
CNBC
Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.
Read the full story
This is a short summary. The complete article is published by CNBC.
Headline and summary aggregated from public news feeds. For information only — not financial advice.